- Molecular NameMethotrimeprazine
- SynonymLevomepromazine
- Weight328.48
- Drugbank_IDDB01403
- ACS_NO60-99-1
- Show 3D model
- LogP (experiment)4.68
- LogP (predicted, AB/LogP v2.0)4.93
- pka9.2
- LogD (pH=7, predicted)2.79
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.84
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors0
- No.of HBond Acceptors3
- No.of Rotatable Bonds5
- TPSA41.01
- StatusFDA approved
- AdministrationOral, seldom intramuscular
- PharmacologyAn aliphatic phenothiazine neuroleptic drug. It is a low-potency antipsychotic (approximately half as potent as chlorpromazine) with strong analgesic and antiemetic properties.
- Absorption_valueN/A
- Absorption (description)Levomepromazine has an incomplete oral bioavailability
- Caco_2N/A
- Bioavailability50.0
- Protein bindingN/A
- Volume of distribution (VD)30 l/kg
- Blood/Plasma Partitioning ratio (D_blood)Plasma:whole blood ratio, about 1.2 but there is considerable intersubject variation.
- MetabollsmLevomepromazine is metabolized in the liver to a sulfoxide, a glucuronide, and a demethylated metabolite.
- Half lifelevomepromazine 16~78 h (mean 27), sulfoxide metabolite 10~30 h (mean 20).
- ExcretionIn feces and urine (metabolites), unchanged drug only 1%
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityIn a 42-year-old male who committed suicide by ingesting levomepromazine, the following postmortem body-fluid concentrations of levomepromazine, desmethyllevomepromazine and levomepromazine sulfoxide were reported, respectively: blood 4.1, 2.0, and 1.8 mg/L, urine 0.80, 1.2, and 8.9 mg/L, bile 70, 35, and 26 mg/L, vitreous humour 0.25, 0.20, and 0.90 mg/L. No other drugs were detected. [S. P. Avis and M. D. Holzbecher,J. Forensic Sci.,1996, 41, 1080–1081.]
- LD50 (rat)N/A
- LD50 (mouse)N/A